Leslie M. Shaw, PhD
Professor of Pathology and Laboratory Medicine at the Hospital of the University of Pennsylvania
Director, Clinical Toxicology Laboratory
University of Pennsylvania Perelman School of Medicine
Contact InformationHospital of the University of Pennsylvania
7.103 Founders Pavilion
3400 Spruce Street
Philadelphia, PA 19104
Office: (215) 662-6575
Fax: (215) 662-7529
Email: Les.Shaw@uphs.upenn.edu; shawlmj@mail.med.upenn.edu
Specialty Division
Laboratory Medicine
Research Expertise
Development, validation and implementation of neurodegenerative diseases biomarkers in cerebrospinal fluid and plasma into treatment trials and clinical studies (eg, ADNI study; UPENN ADRC; PPMI study). These studies include the use of manual and highly automated immunoassays and for amyloid beta(1-42), U-p53AZ and for total tau the use of high sensitivity UPLC/tandem mass spectrometry. Multi-modal statistical analyses of these study data to address several questions including the diagnostic utilities of these biomarkers; assessments of the longitudinal trajectories of these biomarkers in AD, MCI and cognitively normal controls to assess the neuropathological changes over time in these individuals.
Clinical Expertise
Measurement and interpretation of the toxicokinetics of drugs and toxins in patients affected by them. Interpretation of the pharmacokinetics of immunosuppressant maintenance medications in transplant patients.
Other Expertise
Development and implementation of mass spectrometry-based methods for measuring small molecules of clinical utility including therapeutic drugs, toxins and special chemistry tests including Xylazine; 25-OH vitamin D; and biologicals, eg, Infliximab. Development, validation and implementation of plasma based Alzheimers Disease biomarkers.
Education
B.S. (Cum Laude, Chemistry), LeMoyne College, Syracuse, New York, 1962
Ph.D. (Biochemistry), S.U.N.Y. at Upstate Medical Center, 1968
Specialty Certification
American Board of Clinical Chemistry, 1973
American Board of Clinical Chemistry in Toxicological Chemistry, 1990
USC School of Medicine, Laboratory of Applied Pharmacokinetics, 1995
Postgraduate Training
NIH Post doctoral Fellowship Department of Molecular Biology, The Johns Hopkins University, Baltimore, MD, 1968-1970
Fellow, Neuroscience Research Program, 1969-1969
NIH Postdoctoral Fellowship, William Pepper Laboratories, Hospital of the University of Pennsylvania, Philadelphia, PA, 1970-1972
Awards and Honors
Norman Kubasik Lectureship Award, Upstate New York AACC Meeting, 1992-1992
Outstanding Speaker Award, 1995, 1996, 1997, 2000, 2001, 2002, 2003, American Association for Clinical Chemistry, 1995-2003
Reinhold Award, Philadelphia Section, AACC, 1995-1995
IATDMCT Charles Pippenger Award for Outstanding Contributions in Therapeutic Drug Monitoring, 1999-1999
The Peter C Nowell Teaching Award, University of Pennsylvania Medical Center, 1999-1999
The Kevin Salhany, MD, Award for Excellence in Clinical Teaching; Department of Pathology and Laboratory Medicine, University of Pennsylvania Medical Center, 2005-2005
LeMoyne College - Distinguished Alumni Award, 2012-2012
AACC Lifetime Achievement Award in Clinical Chemistry and Laboratory Medicine., 2013
Memberships and Professional Organizations
American Chemical Society, 1962 - present
Alpha Sigma Nu, National Jesuit Honor Society, 1962 - 1964
American Association for Clinical Chemistry, 1972 - present
Philadelphia Section, American Association for Clinical Chemistry:, 1978 - Present
American Association for the Advancement of Science, 1978 - present
Philadelphia Section, American Association for Clinical Chemistry: 1996 (Program Chairman).
Philadelphia Section, American Association for Clinical Chemistry: 1978, 1978 - Present
International Federation of Clinical Chemistry, 1979 - present
AACC/NACB Task Force on Cyclosporine Monitoring, 1985 - 1987
National Academy of Clinical Biochemistry:, 1986 - present
International Association for Therapeutic Drug Monitoring and Clinical Toxicology, 1989 - present
Therapeutic Drug Monitoring and Clinical Toxicology Division of the AACC:, 1991 - Present
American Society for Mass Spectroscopy, 1991 - 1994
USP Council of Experts,, 2001 - 2002
Society of Toxicology, 2004 - 2007, 2004 - 2007
Alzheimers Association, 2005 - Present
Eli Lilly, 2011 - 2018
Alzheimers Association Global Biomarker Standardization Consortium., 2011 - Present
Roche (Member of Scientific Advisory Board), 2016 - Present
Cerebrospinal Fluid appropriate Use, Criteria Workgroup, Alzheimers Association., 2017 - 2018
FNIH Biomarker Consortium, plasma abeta project team, 2017 - ongoing
FNIH Biomarker Consortium Plasma Aβ Project Team., 2022 - Present
Selected Publications
Evaluation of ATNPD framework and biofluid markers to predict cognitive decline in early Parkinson’s Disease.
Cousins KAQ, Irwin DJ, Tropea TF, Rhodes E, Phillips JS, Chen-Plotkin AS, Brumm MC, Coffey CS, Kang JH, Simuni T, Foroud T, Toga AW, Tanner CM, Kieburtz K, Mollenhauer B, Galasko DR, Hutten S, Weintraub D, Tiderowf AS, Marek K, Kollmorgen G, Poston KL, Shaw LM, The Parkinson’s Progression Marker Initiative., Neurology. In Press, 2024. In Press
Relationships of cognitive measures with cerebrospinal fluid but not imaging biomarkers of Alzheimer Disease vary between black and white individuals.
Bonomi S, Lu R, Schindler SE, Bui Q, Lah JJ, Wolk D, Gleason CE, Sperling R, Roberson ED, Levey AI, Shaw L, Van Hulle C, Benzinger T, Adams M, Manzanares C, Qiu D, Hassentab J, Moulder KL, Balls-Berry JE, Johnson K, Johnson SC, Murchison CF, Luo J, Gremminger E, Agboola F, Grant EA, Hornbeck R, Massoumzadeh P, Keefe S, Dierker D, Gray J, Henson RL, Streitz M, Mechanic-Hamilton D, Morris JC, Xiong C., Ann Neurol. 95(): 495-50., 2024.
ADNI Biomarker Core: A Review of Progress Since 2004 and Future Challenges.
Shaw LM, Korecka M, Lee EB, Cousins KAQ, Vanderstichele H, Schindler SE, Tosun D, DeMarco ML, Brylska M, Wan Y, Burnham S, Sciulli A, Vulaj A, Tropea TF, Chen-Plotkin A, Wolk DA, for the Alzheimer’s Disease Neuroimaging Initiative*., Alz. Dementia. In Press, 2024, in Press.
Baseline levels and longitudinal changes in plasma Aβ42/40 among Black/African American and White individuals.
Xiong C, Luo J, Wolk DA, Shaw LM, Roberson ED, Murchison CF, Henson RL, Benzinger TLS, Bui Q, Agboola F, Grant E, Gremminger E, Moulder KL, Geldmacher DS, Clay OJ, Babulal G, Cruchaga C, Holtzman DM, Bateman RJ, Morris JC, Schindler SE., Nat. Communic,, 2024 - In Press
A cross-sectional study of α-synuclein seed amplification assay in Alzheimer’s disease neuroimaging initiative: Prevalence and associations with Alzheimer’s Disease biomarkers and cognitive function.
Tosun D, Hausle Z, Iwaki H, Thropp P, Lamoureux J, Lee EB, MacLeod K, McEvoy S, Nalls M, Perrin RJ, Saykin AJ, Shaw LM, Singleton AB, Lebovitz R, Weiner MW, Blauwendraat C, for the Alzheimer’s Disease Neuroimaging Initiative., Alz. Dementia. In Press., 2024 - In Press
Biomarkers Consortium Plasma Aβ and Phosphorylated Tau as Predictors of Amyloid and Tau Positivity in Alzheimer’s Disease Project Team. Head-to-head comparison of leading blood tests for Alzheimer’s disease pathology.
Schindler SE, Petersen KK, Saef B, Tosun D, Shaw LM, Zetterberg H, Dage JL, Ferber K, Triana-Baltzer G, Du-Cuny L, Li Y, Coomaraswamy J, Baratta M, Mordashova Y, Saad ZS, Raunig DL, Ashton NJ, Meyers EA, Rubel CE, Rosenbaugh EG, Bannon AW, Potter WZ, Alzheimer’s Disease Neuroimaging Initiative (ADNI)**, Foundation for the National Institutes of Health (FNIH)., MedRxiv Pre-print., 2024
Blood-based biomarkers for Alzheimer’s disease: current state and future use in a transformed global healthcare landscape.
Hampel H, Hu Y, Cummings J, Mattke S, Iwatsubo T, Nakamura A, Vellas B, O’Bryant S, Shaw LM, Cho M, Batrla R, Vergallo A, Blennow K, Dage J, Suzanne E. Schindler., Neuron. 111(18): 2781-2799, 2023
Assessments of the utilities of CSF NPTX2 for disease progression in cognitively normal individuals who progress to clinical MCI and AD.
Shaw LM, Galasko D., Ann Neurol. Editorial - Invited Commentary. 94(4): 618-19, 2023
Safety and tolerability of lumbar puncture for the evaluation of Alzheimer's disease.
Baldaranov D, Garcia V, Miller G, Donohue MC, Shaw LM, Weiner M, Petersen RC, Aisen P, Raman R, Rafii MS., Alzheimer's Dement (Amst). 18(15 (2)): e12431, 2023
Plasma phosphorylated tau181 predicts cognitive and functional decline.
Tropea TF, Waligorska T, Xie SX, Nasrallah IM, Cousins KAQ, Trojanowski JQ, Grossman M, Irwin DJ, Weintraub D, Lee EB, Wolk DA, Chen-Plotkin AS, Shaw LM; Alzheimer's Disease Neuroimaging Initiative., Ann Clin Transl Neurol. 10(1): 18-31, 2023, PMID:36518085
